Green biologics: The algal chloroplast as a platform for making biopharmaceuticals

68Citations
Citations of this article
194Readers
Mendeley users who have this article in their library.

Abstract

Most commercial production of recombinant pharmaceutical proteins involves the use of mammalian cell lines, E. coli or yeast as the expression host. However, recent work has demonstrated the potential of eukaryotic microalgae as platforms for light-driven synthesis of such proteins. Expression in the algal chloroplast is particularly attractive since this organelle contains a minimal genome suitable for rapid engineering using synthetic biology approaches; with transgenes precisely targeted to specific genomic loci and amenable to high-level, regulated and stable expression. Furthermore, proteins can be tightly contained and bio-encapsulated in the chloroplast allowing accumulation of proteins otherwise toxic to the host, and opening up possibilities for low-cost, oral delivery of biologics. In this commentary we illustrate the technology with recent examples of hormones, protein antibiotics and immunotoxins successfully produced in the algal chloroplast, and highlight possible future applications.

Cite

CITATION STYLE

APA

Taunt, H. N., Stoffels, L., & Purton, S. (2018, September 26). Green biologics: The algal chloroplast as a platform for making biopharmaceuticals. Bioengineered. Taylor and Francis Inc. https://doi.org/10.1080/21655979.2017.1377867

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free